bird flu stocks
birdflustocks.com » bird flu stocks  » 
bird flu stocks
BioNTech/Pfizer: Pfizer and BioNTech resolve mRNA patent lawsuit filed by Promosome
By admin | |
No financial terms were disclosed. https://www.reuters.com/legal/pfizer-resolves-promosome-patent-lawsuit-over-covid-19-vaccine-2023-10-05/
Moderna: mRNA-1010 Seasonal Influenza Vaccine phase 3 study successfully completed
By admin | |
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-scale-down-manufacturing-covid-vaccine-2023-09-13/
Cidara Therapeutics/Johnson & Johnson: CD388 cooperation will continue, stock +26%
By admin | |
Cidara to receive a $7 million milestone payment and is
Vir Biotechnology: VIR-2981 appears on pipeline page, indicating GSK collaboration
By admin | |
While there is no press release with further information, the
Moderna: mRNA-1010 phase 3 study data coming soon?
By admin | |
Official Title: A Phase 3, Randomized, Stratified, Observer-blind, Active-Controlled Study
Vir Biotechnology: VIR-2482 phase 2 study failed, stock drops 44%
By admin | |
https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-topline-data-phase-2-peninsula-trial
BioCryst Pharmaceuticals: BofA upgraded BioCryst (BCRX) to Buy from Neutral with a $10 price target
By admin | |
BofA upgraded BioCryst (BCRX) to Buy from Neutral with a
Cidara Therapeutics: CD388 phase 2 study data coming soon?
By admin | |
Official Title: A Proof-of-concept, Randomized, Double-blind, Placebo-controlled, Phase 2a Study